Inhibition of recombinant human wild-type N-terminal His-tagged PDIA1 expressed in Escherichia coli strain BL21(DE3) using bovine insulin as substrate preincubated for 1 hr followed by substrate addition
Inhibition of N-(4-(5,5-Difluoro-1,3,7,9-tetramethyl-5H-4(Gamma4),5(Gamma4)-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl))-N-(2-(4-((6-hydroxybenzo[d]-[1,3]dioxol-5-yl)(piperidin-1-yl)methyl)benzamido)ethyl)-benzamide binding to PDIA1 in human U-87 MG cell lysates measured after 24 hrs by PAGE analysis
Inhibition of N-(4-(5,5-Difluoro-1,3,7,9-tetramethyl-5H-4(Gamma4),5(Gamma4)-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl))-N-(2-(4-((6-hydroxybenzo[d]-[1,3]dioxol-5-yl)(piperidin-1-yl)methyl)benzamido)ethyl)-benzamide binding to recombinant PDIA2 (unknown origin) measured after 24 hrs by PAGE analysis
Inhibition of N-(4-(5,5-Difluoro-1,3,7,9-tetramethyl-5H-4(Gamma4),5(Gamma4)-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-10-yl))-N-(2-(4-((6-hydroxybenzo[d]-[1,3]dioxol-5-yl)(piperidin-1-yl)methyl)benzamido)ethyl)-benzamide binding to recombinant PDIA3 (unknown origin) measured after 24 hrs by PAGE analysis